The new product Lipofectamine LTX is designed to deliver DNA into the cell, the first critical step in characterising gene function. Detailed understanding of this process will in turn, help researchers learn about the molecular basis of disease formation and develop potential therapeutic strategies to combat disease.
Within this new product, Invitrogen have shown a high level of transfection efficiency and protein expression with more than 90 per cent viability for a wide range of cells, including primary neuronal cells and other disease-relevant cell types.
The introduction of Lipofectamine LTX closely follows Invitrogen's release earlier this year of another member of the Lipofectamine product line.
Lipofectamine RNAi MAX is a RNAi-specific transfection reagent that offers high transfection efficiency and low toxicity profiles on a wide variety of cell types for siRNA gene knockdown experiments.
"These technologies add significant capabilities to a transfection portfolio that is already widely adopted throughout the industry and was instrumental in establishing applications such as RNAi and stem cell research," said Claude Benchimol, senior vice president of research and development for Invitrogen.
"Our commitment to continual improvement in our core technologies is demonstrated in the release of Lipofectamine LTX and Lipofectamine RNAi MAX," said Mark Gardner, Invitrogen's vice president of Molecular Biology Essentials.
"Lipofectamine 2000 is one of our company's top products, and with the advances these new reagents provide, we have a chance to support new and rapidly expanding research applications with the next generation of gene delivery solutions," he added.